

Royal College of Paediatrics and Child Health

Clinical Standards

5-11 Theobalds Road, London WC1X 8SH

Tel: 020 7092 6160 | Fax: 020 7092 6001 | clinical.standards@rcpch.ac.uk

NICE MTA Pharmedgen for the treatment of venom allergy Appraisal Consultation Document (ACD) Stakeholder comments

With thanks to:



Section number	Comments
General	This is an excellent appraisal which has appropriately considered the needs of children with venom allergy.
General	While the recommendation is that this should only be used in a specialist centre, it does not define what co-dependencies are required. These must include the immediate proximity of intensive care relevant to the ages of patients being so treated, ie PICU for children.
General	Nothing to add, from a pharmaceutical viewpoint, to those comments already made by RCPCH.
1	Recommendations – in view of the conclusions of the evaluation it would be appropriate to recommend that a national data base of the use of this therapy is created.

Evaluation report	
Page number	Comments
General	Most DGH pharmacists would be unfamiliar with this particular desensitisation technique. Is this a tertiary care type procedure (and so interested in medical view) and might it be appropriate to draw attention to this?
3.1.2 table 4	While the published data do not indicate much difference in the frequency of adverse reactions between standard and rush protocols, allergy experts' anecdotal experience shows that they are considerably more common and more serious during rush protocols. Rush may be indicated if the patient lives far from a hospital or because of timing ie approaching Spring/Summer.

Please email clinical.standards@rcpch.ac.uk if you have any questions about this form.